

Fig.1




Fig.2




Fig.3






Fig.4



## Fig.5

				•					
1	10	20	30	40	50	60			
MNSGAMRIHSKGHFQGGIQVKNEKNRPSLKS <u>LKTDNRPEKSKCKPLWGKVFYLDLPSVTI</u>									
Into Crauta.	Dbf4 motif-N								
61	70	80	90	100	110	120			
					ESAVTAETTS	o H			
<u>SEKLOKDIKDLGGRVEEFLSKDISYLISNKKEAKFAOT</u> LGRISPVPSPESAYTAETTSPH									
121	130	140	150	160	170	180			
PSHDGSSFKSPDTVCLSRGKLLVEKAIKDHDFIPSNSILSNALSWGVKILHIDDIRYYIE									
524DG221 V21D1 ACD2VGVTPA EVYLVDUDI 152N2 TD2N4TQ104 AV111111111111111111111111111111111111									
181	190	200	210	220	230	240			
QKKKELYLLKKSSTSVRDGGKRVGSGAQKTRTGRLKKPFVKVEDMSQLYRPFYLQLTNMP									
ÓWWENT THE CONTRACTOR OF THE C									
241	250	260	270	280	290	300			
	FINYSIQKPCSPFDVDKPSSMQKQTQVKLRIQTDGDKYGGTSIQLQLKEKKKKGYCECCL								
	Dbf4 motif-C								
301	310	320	330	340	350	360			
OKYEDLET	HLLSEQHRNF.	HOSNOTOVVD	DIASKTALDE	AFIFVDILVV	TKIKI 2 4 GOD	) F			
261	270	300	390	400	410	420			
361	370	380	333						
VSASVLKK	TEQKEKVELQ	HISQKDCQED	DTTVKEQNFL	YKETQETEKK	TTLISEATEU	PS			
421	430	440	450	460	470	480			
		_							
NELRGLNEKMSNKCSMLSTAEDDIRQNFTQLPLHKNKQECILDISEHTLSENDLEELRVD									
481	490	500	510	520	530	540			
	SVHVSDFSTD				HDSGLITINS	so			
minemign	21.11021012		01 1 2 1 1 1 1 1 1 1 1			_ ~			
541	550	560	570	580	590 ·	600			
	APFHTPPEEP			KTTI.GRNRKE	ENLEPNAEFDK	RT			
DIIDI VQIN		MEEDI KIKIDO	EL BORLINGO	11222014114					
601	610	620	630	640	650	660			
EFITOEEN	RICSSPVOSL	LDLFOTSEEK	SEFLGFTSYT	EKSGICNVLI	IWEEENSDNL	ĻT			
EFITQEENRICSSPVQSLLDLFQTSEEKSEFLGFTSYTEKSGICNVLDIWEEENSDNLLT									
661	670 674								
AFFSSPST	STFTGF*								

Fig.6



## Dbf4 motif-C

H37	Z63: KQTQVKLRIQTDGDKYGGTSIQLQLKEKKKK <mark>GYCEQC</mark> LQ <u>KYE</u> QLETHLLSEQHRNEAQSN 322	
mu-H37	:BOACPKLRINMDGDKC-GTPVOLOLKEKRKKGYCFCGLGKYEDLETHILLSEKIRNEAOSN	
Dm-H37	:PSLQELKKQSAIPNSPRSNCREPIDSSENQCGMCEICKLEYDILNIHLQSKDHELFAKNS	
Dbf4	619: KKSTSTNVTLHFNAQTACTAQPVKKETVKNSGYCLNGRVKYESLEQHILVSECHLSFAE-N 677	

Fig.7




Fig.8





Fig.9








Fig.10



11/20

Fig.11



12/20

Fig. 12





Fig.13



14/20

Fig. 14

#1 #2 #3 #4 #5 #6 #7 #8

H37

Cyclin E

G3PDH






Fig.15







Fig. 16





relative Cyclin E mRNA



1.7/20

Fig.17




Fig. 18




Fig.19




Fig.20

## Microinjection with

